Key result
Plasma Nt-pro-BNP levels above the median (>12,782 pg/mL) were significant predictors of 30-day mortality in patients with cardiogenic shock (P<0.001).
Why the study?
Do elevated plasma Nt-pro-BNP and IL-6 levels at admission predict 30-day mortality in patients with cardiogenic shock?
Observational (n=58)
Yes
Do elevated plasma Nt-pro-BNP and IL-6 levels at admission predict 30-day mortality in patients with cardiogenic shock?
Absolute Event Rate: 93.7% vs 26.3%
p-value: p=<0.001
Elevated Nt-pro-BNP and IL-6 levels at ICU admission are strong, complementary predictors of 30-day mortality in patients with cardiogenic shock.
May aid short-term risk stratification with Nt-pro-BNP in cardiogenic shock; leaves open validation and therapeutic utility.
OBJECTIVE: Plasma N-terminal pro-B-type natriuretic peptide (Nt-pro-BNP) levels are frequently elevated in critically ill patients and are associated with an increased mortality. In this study, we determined Nt-pro-BNP levels in patients with cardiogenic shock (CS) and evaluated its association with clinical and hemodynamic parameters and 30-day mortality. DESIGN: Retrospective study. SETTING: Two, eight-bed intensive care units at a university and a community hospital. PATIENTS: Retrospective study on stored plasma samples of 58 patients with CS, obtained at admission to the intensive care unit. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Massively elevated Nt-pro-BNP concentrations showed no significant association with duration of shock, total Sequential Organ Failure Assessment score, or invasive hemodynamic parameters at the time of blood sampling but a significant association with estimated glomerular filtration rate (p < 0.001), C-reactive protein (p = 0.03), age (p = 0.005), and body weight (p = 0.03). Both in univariate and multivariate survival analyses, Nt-pro-BNP levels above the median (>12,782 pg/mL) were significant predictors of 30-day mortality (p < 0.001) and showed a complementary role with interleukin (IL)-6 in predicting outcome. Patients with IL-6 >195 pg/mL and Nt-pro-BNP above the median value had the highest 30-day mortality (93.7%), whereas patients with lower IL-6 levels together with lower Nt-pro-BNP levels had significantly better survival (mortality rate 26.3%). Among patients who had acute myocardial infarction, those with Nt-pro-BNP concentrations above the median level showed a highly impaired clinical course even if coronary revascularization was successful (30-day mortality 90.9% vs. 29.4%, p = 0.001), whereas survival of patients with unsuccessful revascularization did not differ significantly with respect to the median of Nt-pro-BNP (30-day survival rate 81.8% vs. 75.0%, p = 0.71). CONCLUSION: The massive elevations of Nt-pro-BNP observed in the early phase of CS seem to be independent of ventricular performance. Nt-pro-BNP levels are nevertheless predictive of 30-day survival in patients with CS especially in those with successful revascularization and might be used in combination with IL-6 for estimation of outcome early on.
No takes yet. Share an insight, caveat, or question.
Járai et al. (2009) conducted an observational in Cardiogenic shock (n=58). Nt-pro-BNP and IL-6 levels vs. Lower Nt-pro-BNP and IL-6 levels was evaluated on 30-day mortality (p=<0.001). Plasma Nt-pro-BNP levels above the median (>12,782 pg/mL) were significant predictors of 30-day mortality in patients with cardiogenic shock (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: